{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:51:54Z","timestamp":1791978714091,"version":"4.4.0"},"reference-count":348,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology. These principles have been critical in the development of immunotherapy in the laboratory and in the implementation of immunotherapy in the clinic. This improved understanding of immunotherapy, enhanced by increased insights into the mechanism of tumor immune response and its evasion by tumors, now permits manipulation of this interaction and elucidates the therapeutic role of immunity in cancer. Also important, this improved understanding of immunotherapy and the mechanisms underlying immunity in cancer has fueled an expanding array of new therapeutic agents for a variety of cancers. Pegylated interferon\u2010\u03b12b as an adjuvant therapy and ipilimumab as therapy for advanced disease, both of which were approved by the United States Food and Drug Administration for melanoma in March 2011, are 2 prime examples of how an increased understanding of the principles of tumor biology and immunology have been translated successfully from the laboratory to the clinical setting. Principles that guide the development and application of immunotherapy include antibodies, cytokines, vaccines, and cellular therapies. The identification and further elucidation of the role of immunotherapy in different tumor types, and the development of strategies for combining immunotherapy with cytotoxic and molecularly targeted agents for future multimodal therapy for cancer will enable even greater progress and ultimately lead to improved outcomes for patients receiving cancer immunotherapy. CA Cancer J Clin 2012. \u00a9 2012 American Cancer Society.<\/jats:p>","DOI":"10.3322\/caac.20132","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T10:01:07Z","timestamp":1336644067000},"page":"309-335","source":"Crossref","is-referenced-by-count":348,"title":["Immunotherapy of cancer in 2012"],"prefix":"10.3322","volume":"62","author":[{"given":"John M.","family":"Kirkwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane","family":"Zarour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480200900104"},{"issue":"1","key":"e_1_2_13_3_2","first-page":"S11","article-title":"High\u2010dose recombinant interleukin\u20102 therapy in patients with metastatic melanoma: long\u2010term survival update","volume":"6","author":"Atkins MB","year":"2000","journal-title":"Cancer J Sci Am."},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_2_13_5_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","article-title":"A phase II study of interleukin\u20102 and lymphokine\u2010activated killer cells in patients with metastatic malignant melanoma","volume":"7","author":"Dutcher JP","year":"1989","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1650"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1963"},{"key":"e_1_2_13_9_2","first-page":"1","article-title":"A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study","volume":"276","author":"Nauts HC","year":"1953","journal-title":"Acta Med Scand Suppl."},{"key":"e_1_2_13_10_2","first-page":"67","article-title":"Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms","volume":"44","author":"Nathanson L","year":"1976","journal-title":"Natl Cancer Inst Monogr."},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"e_1_2_13_12_2","first-page":"913","article-title":"Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins","volume":"42","author":"Mazumder A","year":"1982","journal-title":"Cancer Res."},{"key":"e_1_2_13_13_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.127.1.266","article-title":"Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens","volume":"127","author":"Strausser JL","year":"1981","journal-title":"J Immunol."},{"key":"e_1_2_13_14_2","first-page":"723","article-title":"Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society phase II trial","volume":"68","author":"Krown SE","year":"1984","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.4.336"},{"issue":"4","key":"e_1_2_13_16_2","first-page":"7","article-title":"Melanoma: therapeutic options with recombinant interferons","volume":"12","author":"Kirkwood JM","year":"1985","journal-title":"Semin Oncol."},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-32"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33078"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.7"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2444"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2370"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.052"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/302305a0"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3131876"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_13_27_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8536","article-title":"Neoadjuvant ipilimumab in patients with stage IIIB\/C melanoma: immunogenicity and biomarker analysis","volume":"29","author":"Tarhini AA","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_28_2","first-page":"1302","article-title":"CTLA\u20104\u2010blocking immunotherapy with ipilimumab for advanced melanoma","volume":"24","author":"Tarhini AA","year":"2010","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1100"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5449"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.002005"},{"key":"e_1_2_13_32_2","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin U","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"e_1_2_13_33_2","first-page":"6506","article-title":"The alternative open reading frame of LAGE\u20101 gives rise to multiple promiscuous HLA\u2010helper 1\u2010type tumor\u2010reactive CD4+ T cells","volume":"63","author":"Mandic M","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1751"},{"key":"e_1_2_13_35_2","first-page":"213","article-title":"NY\u2010ESO\u20101 119\u2010143 is a promiscuous major histocompatibility complex class II T\u2010helper epitope recognized by Th1\u2010 and Th2\u2010type tumor\u2010reactive CD4+ T cells","volume":"62","author":"Zarour HM","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_13_36_2","unstructured":"Cancer Immunity. Mapping and binding analysis of peptides derived from the tumor\u2010associated antigen surviving for eight HLA alleles. Available at:http:\/\/www.cancerimmunity.org\/v5p6\/050106.pdf. Accessed September 6 2011."},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1231"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-321"},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23373"},{"key":"e_1_2_13_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318183af0b"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800080105"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/31002"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083317"},{"key":"e_1_2_13_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"e_1_2_13_45_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903612"},{"key":"e_1_2_13_46_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.776"},{"key":"e_1_2_13_47_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703395104"},{"key":"e_1_2_13_48_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610383104"},{"key":"e_1_2_13_49_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000808"},{"key":"e_1_2_13_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0274"},{"key":"e_1_2_13_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1544"},{"key":"e_1_2_13_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0486"},{"key":"e_1_2_13_53_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.6169"},{"key":"e_1_2_13_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2517"},{"key":"e_1_2_13_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792"},{"key":"e_1_2_13_56_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803245"},{"key":"e_1_2_13_57_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637"},{"key":"e_1_2_13_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/32588"},{"key":"e_1_2_13_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00015-3"},{"key":"e_1_2_13_60_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.8.1183"},{"key":"e_1_2_13_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(99)01547-9"},{"key":"e_1_2_13_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.03.002"},{"key":"e_1_2_13_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1592"},{"key":"e_1_2_13_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0588"},{"key":"e_1_2_13_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06175"},{"key":"e_1_2_13_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60241-X"},{"key":"e_1_2_13_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.08.004"},{"key":"e_1_2_13_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1806"},{"key":"e_1_2_13_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_2_13_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1924"},{"key":"e_1_2_13_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6818"},{"key":"e_1_2_13_72_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.6.3231"},{"key":"e_1_2_13_73_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.9.4507"},{"key":"e_1_2_13_74_2","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.4049\/jimmunol.161.6.2804","article-title":"Prostaglandin E2 induces the final maturation of IL\u201012\u2010deficient CD1a+CD83+ dendritic cells: the levels of IL\u201012 are determined during the final dendritic cell maturation and are resistant to further modulation","volume":"161","author":"Kalinski P","year":"1998","journal-title":"J Immunol."},{"key":"e_1_2_13_75_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25947"},{"key":"e_1_2_13_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00422.x"},{"key":"e_1_2_13_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00399.x"},{"key":"e_1_2_13_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00702.x"},{"key":"e_1_2_13_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(02)00333-3"},{"key":"e_1_2_13_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.02.005"},{"key":"e_1_2_13_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.07.001"},{"key":"e_1_2_13_82_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702"},{"key":"e_1_2_13_83_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.593"},{"key":"e_1_2_13_84_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.8053"},{"key":"e_1_2_13_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2003.10.001"},{"key":"e_1_2_13_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690164"},{"key":"e_1_2_13_87_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01725.x"},{"key":"e_1_2_13_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.05.008"},{"key":"e_1_2_13_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.05.013"},{"key":"e_1_2_13_90_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/BD-2004-20114","article-title":"The role of chemokines in the biology and therapy of breast cancer","volume":"20","author":"Walser TC","year":"2004","journal-title":"Breast Dis."},{"key":"e_1_2_13_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0196-52"},{"key":"e_1_2_13_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-328"},{"key":"e_1_2_13_93_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6909"},{"key":"e_1_2_13_94_2","first-page":"5091","article-title":"Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients","volume":"9","author":"de Vries IJ","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_13_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0084-8"},{"key":"e_1_2_13_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5252"},{"key":"e_1_2_13_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3223"},{"key":"e_1_2_13_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.02.003"},{"key":"e_1_2_13_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429"},{"key":"e_1_2_13_100_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200607030-00006"},{"key":"e_1_2_13_101_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.8.1275"},{"key":"e_1_2_13_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2994"},{"key":"e_1_2_13_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2299"},{"key":"e_1_2_13_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32832a1868"},{"key":"e_1_2_13_105_2","doi-asserted-by":"publisher","DOI":"10.3181\/0708-MR-226"},{"key":"e_1_2_13_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(96)00079-8"},{"key":"e_1_2_13_107_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3640"},{"key":"e_1_2_13_108_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830271209"},{"key":"e_1_2_13_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0360"},{"key":"e_1_2_13_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0017"},{"key":"e_1_2_13_111_2","first-page":"12","article-title":"Effective migration of antigen\u2010pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state","volume":"63","author":"de Vries IJ","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_13_112_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj138"},{"key":"e_1_2_13_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3466"},{"key":"e_1_2_13_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_2_13_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1261"},{"key":"e_1_2_13_116_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1107737"},{"key":"e_1_2_13_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.07.038"},{"key":"e_1_2_13_118_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.10.1303"},{"key":"e_1_2_13_119_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011662"},{"key":"e_1_2_13_120_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2366"},{"key":"e_1_2_13_121_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2251"},{"key":"e_1_2_13_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211316.15278.6e"},{"key":"e_1_2_13_123_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:36:1:137"},{"key":"e_1_2_13_124_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.216"},{"key":"e_1_2_13_125_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803473"},{"key":"e_1_2_13_126_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181a1c24e"},{"key":"e_1_2_13_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.07.031"},{"key":"e_1_2_13_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636329"},{"key":"e_1_2_13_129_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021466"},{"key":"e_1_2_13_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1569"},{"key":"e_1_2_13_131_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01726"},{"key":"e_1_2_13_132_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041645"},{"key":"e_1_2_13_133_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2486"},{"key":"e_1_2_13_134_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.6.3797"},{"key":"e_1_2_13_135_2","first-page":"319","article-title":"Ectopic T\u2010bet expression licenses dendritic cells for IL\u201012\u2010independent priming of type 1 T cells in vitro","volume":"84","author":"Lipscomb MW","year":"2008","journal-title":"J Immunol."},{"key":"e_1_2_13_136_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902062"},{"key":"e_1_2_13_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I"},{"key":"e_1_2_13_138_2","doi-asserted-by":"publisher","DOI":"10.1309\/4EJ9KL7CGDENVVLE"},{"key":"e_1_2_13_139_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2059"},{"key":"e_1_2_13_140_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6494"},{"key":"e_1_2_13_141_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7744"},{"key":"e_1_2_13_142_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05277"},{"key":"e_1_2_13_143_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0363"},{"key":"e_1_2_13_144_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1246"},{"key":"e_1_2_13_145_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03248.x"},{"key":"e_1_2_13_146_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910560617"},{"key":"e_1_2_13_147_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:29:1-3:187"},{"key":"e_1_2_13_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(02)00365-5"},{"key":"e_1_2_13_149_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v21.i1-3.110"},{"key":"e_1_2_13_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_2_13_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-380890-5.00003-X"},{"key":"e_1_2_13_152_2","series-title":"Cancer: Principles and Practice of Oncology","first-page":"21","author":"Campoli M","year":"2009"},{"key":"e_1_2_13_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1137"},{"key":"e_1_2_13_154_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902750114"},{"key":"e_1_2_13_155_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.108"},{"key":"e_1_2_13_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.013"},{"key":"e_1_2_13_157_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1298"},{"key":"e_1_2_13_158_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1321"},{"key":"e_1_2_13_159_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6360"},{"key":"e_1_2_13_160_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8957"},{"key":"e_1_2_13_161_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0507"},{"key":"e_1_2_13_162_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248609"},{"key":"e_1_2_13_163_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2345"},{"key":"e_1_2_13_164_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0463"},{"key":"e_1_2_13_165_2","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125","author":"Jerne NK","year":"1974","journal-title":"Ann Immunol (Paris)."},{"key":"e_1_2_13_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60251-8"},{"key":"e_1_2_13_167_2","first-page":"2228","article-title":"Antibody response to murine anti\u2010GD2 monoclonal antibodies: correlation with patient survival","volume":"54","author":"Cheung NK","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_13_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(05)93006-6"},{"key":"e_1_2_13_169_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_13_170_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"e_1_2_13_171_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_13_172_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn020"},{"key":"e_1_2_13_173_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_13_174_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_13_175_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.31522"},{"key":"e_1_2_13_176_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_2_13_177_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9170"},{"key":"e_1_2_13_178_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"e_1_2_13_179_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043186"},{"key":"e_1_2_13_180_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_13_181_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_13_182_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"e_1_2_13_183_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_2_13_184_2","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1385\/MO:19:2S:S49","article-title":"Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B\u2010cLL","volume":"19","author":"Kennedy B","year":"2002","journal-title":"Med Oncol."},{"key":"e_1_2_13_185_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_2_13_186_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"e_1_2_13_187_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_13_188_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"e_1_2_13_189_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31405"},{"key":"e_1_2_13_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90002-9"},{"key":"e_1_2_13_191_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708594105"},{"key":"e_1_2_13_192_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.2.1052"},{"key":"e_1_2_13_193_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0028"},{"key":"e_1_2_13_194_2","doi-asserted-by":"crossref","unstructured":"RibasA HauschildA KeffordR et al.Phase III open\u2010label randomized comparative study of tremelimumab (CP\u2010675 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral] [abstract]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30\u2010June 3 2008; Chicago IL Abstract LBA9011.","DOI":"10.1200\/jco.2008.26.15_suppl.lba9011"},{"key":"e_1_2_13_195_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_13_196_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_13_197_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.8524","article-title":"Phase II evaluation of tremelimumab (Treme) combined with high\u2010dose interferon alpha\u20102b (HDI) for metastatic melanoma","volume":"28","author":"Tarhini AA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_198_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.5394"},{"key":"e_1_2_13_199_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_2_13_200_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"e_1_2_13_201_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803648"},{"key":"e_1_2_13_202_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813367106"},{"key":"e_1_2_13_203_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710441105"},{"key":"e_1_2_13_204_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.1089.65.3"},{"key":"e_1_2_13_205_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123141"},{"key":"e_1_2_13_206_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_2_13_207_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.02.001"},{"key":"e_1_2_13_208_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"e_1_2_13_209_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_2_13_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"e_1_2_13_211_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319"},{"key":"e_1_2_13_212_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"e_1_2_13_213_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"e_1_2_13_214_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0428"},{"key":"e_1_2_13_215_2","first-page":"6501","article-title":"B7\u2010H1 blockade augments adoptive T\u2010cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome SE","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_13_216_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24899"},{"key":"e_1_2_13_217_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406351101"},{"key":"e_1_2_13_218_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2746"},{"key":"e_1_2_13_219_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079"},{"key":"e_1_2_13_220_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=CT\u2010011+."},{"key":"e_1_2_13_221_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3006","article-title":"Safety and activity of MDX\u20101106 (ONO\u20104538), an anti\u2013PD\u20101 monoclonal antibody, in patients with selected refractory or relapsed malignancies","volume":"26","author":"Brahmer JR","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_222_2","article-title":"Phase II experience with MDX\u20101106 (ONO\u20104538), an anti\u2013PD\u20101 monoclonal antibody, in patients with selected refractory or relapsed malignancies","volume":"27","author":"Brahmer JR","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_223_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrial.gov\/ct2\/results?term=MDX\u20101106."},{"key":"e_1_2_13_224_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-206672"},{"key":"e_1_2_13_225_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00729664?term=MDX\u20101105&rank=1."},{"key":"e_1_2_13_226_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.002"},{"key":"e_1_2_13_227_2","doi-asserted-by":"publisher","DOI":"10.1038\/10503"},{"key":"e_1_2_13_228_2","doi-asserted-by":"publisher","DOI":"10.1038\/10495"},{"key":"e_1_2_13_229_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1882"},{"key":"e_1_2_13_230_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6753"},{"key":"e_1_2_13_231_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082107699"},{"key":"e_1_2_13_232_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3311"},{"key":"e_1_2_13_233_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.10.13251"},{"key":"e_1_2_13_234_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=CP870%2C893."},{"key":"e_1_2_13_235_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0095"},{"key":"e_1_2_13_236_2","first-page":"579","article-title":"Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies","volume":"10","author":"Khubchandani S","year":"2009","journal-title":"Curr Opin Investig Drugs."},{"key":"e_1_2_13_237_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3017"},{"key":"e_1_2_13_238_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008003"},{"key":"e_1_2_13_239_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903440946"},{"key":"e_1_2_13_240_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=SGN\u201040."},{"key":"e_1_2_13_241_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7244"},{"key":"e_1_2_13_242_2","first-page":"5514","article-title":"Therapeutic efficacy of OX\u201040 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth","volume":"60","author":"Kjaergaard J","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_13_243_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.12.6804"},{"key":"e_1_2_13_244_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.2160"},{"key":"e_1_2_13_245_2","unstructured":"Kovacsovics\u2010BankowskiM WalkerE FloydK.Increased CD4 and CD8 memory T cell proliferation following anti\u2010OX40 administration to cancer patients: immunologic assessment of a phase I clinical trial. ISBTC. 2009."},{"key":"e_1_2_13_246_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"e_1_2_13_247_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4910"},{"key":"e_1_2_13_248_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.4.1792"},{"key":"e_1_2_13_249_2","first-page":"3459","article-title":"Anti\u20104\u20131BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor\u2010specific CD8+ T cells","volume":"62","author":"May KF","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_13_250_2","article-title":"Phase I study of BMS\u2010663513, a fully human anti\u2010CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)","author":"Sznol M","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_251_2","unstructured":"ClinicalTrials.gov. 2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=BMS\u2010663513."},{"key":"e_1_2_13_252_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0896-857"},{"key":"e_1_2_13_253_2","doi-asserted-by":"publisher","DOI":"10.1038\/22326"},{"key":"e_1_2_13_254_2","doi-asserted-by":"publisher","DOI":"10.1038\/415331a"},{"key":"e_1_2_13_255_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00271-6"},{"key":"e_1_2_13_256_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.4.1555"},{"key":"e_1_2_13_257_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8578"},{"key":"e_1_2_13_258_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.159.1.11","article-title":"The dominant role of bone marrow\u2010derived cells in CTL induction following plasmid DNA immunization at different sites","volume":"159","author":"Iwasaki A","year":"1997","journal-title":"J Immunol."},{"key":"e_1_2_13_259_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1075"},{"key":"e_1_2_13_260_2","first-page":"3064","article-title":"Alpha\u2010fetoprotein\u2010specific genetic immunotherapy for hepatocellular carcinoma","volume":"59","author":"Vollmer CM","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_13_261_2","first-page":"2865","article-title":"Genetic immunization for the melanoma antigen MART\u20101\/Melan\u2010A using recombinant adenovirus\u2010transduced murine dendritic cells","volume":"57","author":"Ribas A","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_13_262_2","first-page":"1164","article-title":"Immune response to a carcinoembryonic antigen polynucleotide vaccine","volume":"54","author":"Conry RM","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_13_263_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3061"},{"key":"e_1_2_13_264_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020281"},{"key":"e_1_2_13_265_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5491.486"},{"key":"e_1_2_13_266_2","first-page":"2782","article-title":"Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients","volume":"8","author":"Conry RM","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_13_267_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000162779.88687.4c"},{"key":"e_1_2_13_268_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2039"},{"key":"e_1_2_13_269_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181611420"},{"key":"e_1_2_13_270_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.148"},{"key":"e_1_2_13_271_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.041"},{"key":"e_1_2_13_272_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.24.1894"},{"key":"e_1_2_13_273_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.22.13141"},{"key":"e_1_2_13_274_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh028"},{"key":"e_1_2_13_275_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.6816"},{"key":"e_1_2_13_276_2","first-page":"8782","article-title":"alpha\u2010Fetoprotein\u2010specific tumor immunity induced by plasmid prime\u2010adenovirus boost genetic vaccination","volume":"61","author":"Meng WS","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_13_277_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0498-397"},{"key":"e_1_2_13_278_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1999.tb01326.x"},{"key":"e_1_2_13_279_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.11.5905"},{"key":"e_1_2_13_280_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P"},{"key":"e_1_2_13_281_2","doi-asserted-by":"publisher","DOI":"10.1038\/9455"},{"key":"e_1_2_13_282_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00226-0"},{"key":"e_1_2_13_283_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(98)00164-3"},{"key":"e_1_2_13_284_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3964"},{"key":"e_1_2_13_285_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0597"},{"key":"e_1_2_13_286_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-81"},{"key":"e_1_2_13_287_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-45"},{"key":"e_1_2_13_288_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-130"},{"key":"e_1_2_13_289_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2234"},{"key":"e_1_2_13_290_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505113321910"},{"key":"e_1_2_13_291_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1323"},{"key":"e_1_2_13_292_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0071"},{"key":"e_1_2_13_293_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i5.700"},{"key":"e_1_2_13_294_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4565"},{"key":"e_1_2_13_295_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2363"},{"key":"e_1_2_13_296_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02654-4"},{"key":"e_1_2_13_297_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000171291.72039.e2"},{"key":"e_1_2_13_298_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0337-9"},{"key":"e_1_2_13_299_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03231-1"},{"key":"e_1_2_13_300_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.08.012"},{"key":"e_1_2_13_301_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.10.006"},{"key":"e_1_2_13_302_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0811"},{"key":"e_1_2_13_303_2","first-page":"160","article-title":"The structure and regulation of the alpha\u2010fetoprotein and albumin genes","volume":"2","author":"Tilghman SM","year":"1985","journal-title":"Oxf Surv Eukaryot Genes."},{"key":"e_1_2_13_304_2","first-page":"131","volume-title":"Current Cancer Therapeutics","author":"Kirkwood JM","year":"1994"},{"key":"e_1_2_13_305_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.09.004"},{"key":"e_1_2_13_306_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.06.017"},{"key":"e_1_2_13_307_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.01.013"},{"issue":"16","key":"e_1_2_13_308_2","first-page":"5902","article-title":"T\u2010cell responses to HLA\u2010A*0201 immunodominant peptides derived from alpha\u2010fetoprotein in patients with hepatocellular cancer","volume":"9","author":"Butterfield LH","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_13_309_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2856"},{"key":"e_1_2_13_310_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2244"},{"key":"e_1_2_13_311_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.08.021"},{"key":"e_1_2_13_312_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2937"},{"key":"e_1_2_13_313_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23669"},{"key":"e_1_2_13_314_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_13_315_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2006.03.041"},{"key":"e_1_2_13_316_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902932897"},{"key":"e_1_2_13_317_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0775"},{"key":"e_1_2_13_318_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.02.004"},{"key":"e_1_2_13_319_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-001-0255-1"},{"key":"e_1_2_13_320_2","first-page":"2335","article-title":"Expression of myeloid and major histocompatibility antigens on small cell carcinoma of the lung cell lines analyzed by cytofluorography: modulation by gamma\u2010interferon","volume":"46","author":"Ball ED","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_13_321_2","first-page":"6232","article-title":"Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines","volume":"49","author":"Marley GM","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_13_322_2","first-page":"6745","article-title":"Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid","volume":"49","author":"Doyle LA","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_13_323_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.9.616"},{"key":"e_1_2_13_324_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90526-8"},{"key":"e_1_2_13_325_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2924"},{"key":"e_1_2_13_326_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2321"},{"key":"e_1_2_13_327_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1"},{"key":"e_1_2_13_328_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.186"},{"key":"e_1_2_13_329_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.036"},{"key":"e_1_2_13_330_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0482"},{"key":"e_1_2_13_331_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0101"},{"key":"e_1_2_13_332_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2013"},{"key":"e_1_2_13_333_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.08.013"},{"key":"e_1_2_13_334_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.011"},{"key":"e_1_2_13_335_2","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/jco.2010.28.15_suppl.7531","article-title":"Phase II trial of ipilimumab (IPI) and paclitaxel\/carboplatin (P\/C) in first\u2010line stage IIIb\/IV non\u2010small cell lung cancer (NSCLC)","volume":"28","author":"Lynch TJ","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_336_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5807"},{"key":"e_1_2_13_337_2","doi-asserted-by":"crossref","unstructured":"HirschV BoyerM RosellR et al.Randomized phase III trial of paclitaxel\/carboplatin with or without PF\u20103512676 as first line treatment of advanced non\u2010small cell lung cancer (NSCLC). Program and abstracts of the 44th American Society of Clinical Oncology Annual Meeting; Abstract 8016. 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.8016"},{"key":"e_1_2_13_338_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"e_1_2_13_339_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTXMEFOVYWDA6"},{"key":"e_1_2_13_340_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.9.616"},{"key":"e_1_2_13_341_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90526-8"},{"key":"e_1_2_13_342_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2924"},{"key":"e_1_2_13_343_2","doi-asserted-by":"crossref","unstructured":"HirschV BoyerM RosellR et al.Randomized phase III trial of paclitaxel\/carboplatin with or without PF\u20103512676 as first line treatment of advanced non\u2010small cell lung cancer (NSCLC)[abstract]. Paper presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30\u2010June 3 2008; Chicago IL. Abstract 8016.","DOI":"10.1200\/jco.2008.26.15_suppl.8016"},{"key":"e_1_2_13_344_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eb3879"},{"key":"e_1_2_13_345_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1507"},{"key":"e_1_2_13_346_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.6423"},{"key":"e_1_2_13_347_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0253"},{"issue":"18","key":"e_1_2_13_348_2","article-title":"Interferon\u2010\u03b1 as adjuvant therapy for melanoma: an individual patient data meta\u2010analysis of randomised trials","volume":"25","author":"Wheatley K","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_349_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq009"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.20132","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.20132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:19:16Z","timestamp":1762334356000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.20132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":348,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.3322\/caac.20132"],"URL":"https:\/\/doi.org\/10.3322\/caac.20132","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]}}}